Compare Merck & Co., Inc. (MRK) vs ProShares Ultra QQQ ETF (QLD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Merck & Co., Inc. vs ProShares Ultra QQQ ETF — how do they compare? Merck & Co., Inc. trades at $146.06 (market cap $351.28B), while ProShares Ultra QQQ ETF trades at $98.49 (market cap $15.38B). The key difference: Merck & Co., Inc. is far larger — about 22.8× ProShares Ultra QQQ ETF's market cap, and Merck & Co., Inc. pays a 2.39% dividend while ProShares Ultra QQQ ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold Merck & Co., Inc. for 98 Days and ProShares Ultra QQQ ETF for 36 Days on average.
| MRK | QLD | |
|---|---|---|
Market Cap | $351.28B | $15.38B |
Volume | 7,969,665 | 4,844,085 |
Sector | Health | Leveraged / Inverse |
52-Week High | $156.43 | $100.77 |
52-Week Low | $82.49 | $57.16 |
Typical Hold Time | 98 Days | 36 Days |
Enterprise Value | $398.04B | — |
Dividend Yield | 2.39% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Merck (MRK) trades at $145.6, up 1.97% today, with a bearish technical signal but strong fundamental performance. Recent earnings have consistently beaten estimates, and the company is expanding its oncology pipeline through the acquisition of Terns Pharmaceuticals. Revenue growth is steady, with 2025 revenue at $65.01B and net income of $18.25B, though 2026 projections show a significant drop in net income to $3.2B. The stock is supported by a high analyst buy consensus of 68.42% and a price target of $158.78.
The outlook for MRK is mixed; strong earnings beats and strategic acquisitions provide upside potential, but high valuation ratios and a projected earnings decline in 2026 pose risks. Investors should weigh the company's robust profitability and analyst support against execution risks and market volatility.
QLD trades at $98.43, down 1.8% on the day, with technical indicators showing a bullish trend supported by moving averages while oscillators remain neutral. The ETF maintains key support at $96 with resistance at $100. Recent news highlights QLD's resilience compared to higher-leverage alternatives during market downturns, with institutional buying activity noted in recent filings.
The outlook remains cautiously optimistic given the bullish technical setup, though investors face volatility risks from Federal Reserve policy and Nasdaq concentration. QLD's 2x leverage strategy offers a middle ground for Nasdaq-100 exposure, but requires careful risk management during market stress periods.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Merck & Co., Inc.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →About ProShares Ultra QQQ ETF
QLD is a leveraged ETF that seeks daily investment results corresponding to 200% of the daily performance of the NASDAQ-100 Index. It achieves 2x leverage by investing in financial instruments such as swaps and is designed as a tactical trading tool for investors with a bullish (long) view on the NASDAQ-100. Due to the effects of compounding and leverage, the ETF is intended to be held for a single day and is not suitable for long-term investment.
Read more on QLD →
